Drug intelligence / Profile preview

CC2206

Development stage: Preclinical
Lead developer: 环码生物
Modality: RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics

Overview

CC2206 is a circular RNA (circRNA) vaccine candidate being developed by CirCode Biotech. As a circRNA-based therapeutic, it utilizes a covalently closed loop of RNA, which is designed to be more resistant to exonuclease-mediated degradation compared to linear mRNA, potentially leading to more stable and prolonged protein expression. CC2206 is currently in the preclinical stage of development. While the specific target pathogen or antigen has not been disclosed, it is part of CirCode's pipeline of circular RNA therapeutics and vaccines, specifically categorized as a vaccine candidate.

Beyond the preview

Go deeper on CC2206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CC2206.

Explore the full profile